Skip to main content

Table 1 Clinical and demographic characteristics of the participants at baseline

From: How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography

 SSc patients (N = 21)Controls (N = 15)
Female,n(%)18 (85.7)11 (73.3)
Age (years)58.0 (48.5–63.0)55.0 (45.0–63.0)
Smoking habits,n(%)
Never17 (80.9)11 (73.3)
Ex-smoker4 (19.1)4 (26.6)
Disease duration since diagnosis, years10.0 (5.5–14.0)
Disease duration since RP, years14.0 (6.5–16.5)
Limited form,n(%)12 (57.1)
mRSS total8.0 (4.0–15.0)
Phase,n(%) 
Oedematous5 (23.8) 
Fibrotic16 (76.2) 
ANA positive,n(%)20 (95.2)
ACA positive,n(%)9 (42.9)
Anti-Scl 70 positive,n(%)7 (33.3)
Immunosuppressive treatmenta(yes),n(%)6/21
Vasodilators treatmentb(yes),n(%)9/21
  1. Values are in median (Q1–Q3), unless stated otherwise
  2. RP Raynaud phenomenon, ANA anti-nuclear antibody, ACA anti-centromere antibody, mRSS modified Rodnan skin score
  3. aMethotrexate (average dose 15 mg/week, N = 2); prednisolone or equivalent (average dose 5 mg/day (N = 4)
  4. bNifedipine (average dose 30 mg/day, N = 7) and/or pentoxifylline (average dose 800 mg/day, N = 5)